Introduction The growing need for sustainable practices in pharmaceutical manufacturing has stimulated advancements in peptide synthesis. This study focuses on applying green chemistry principles to the synthesis of the Glucagon-Like Peptide-1 analog liraglutide. Material and Methods The safer coupling reagent 1-tert-butyl-3-ethylcarbodiimide (TBEC) was tested in combination with eco-friendly binary solvents such as dimethyl sulfoxide and butyl acetate to propose novel and sustainable solid-phase synthetic and purifcation strategies of liraglutide. Results Two synthetic strategies were developed for liraglutide production. The frst strategy was based on a “direct synthesis”, incorporating a lipidated lysine building block into the peptide sequence, achieving 86% HPLC purity after catch-andrelease purifcation. The second strategy based on “catch-lipidation-and-release” approach, allowed to obtain the peptide precursor without the lipid moiety, which was later linked during a controlled lipidation step. This latter strategy yielded purities exceeding 90% and reduced reliance on preparative HPLC. TBEC minimizes hazardous byproducts, such as hydrogen cyanide, and enhances solvent compatibility, achieving crude purities and yields comparable to conventional syntheses. Conclusion This work underscores the potential of green chemistry to align pharmaceutical innovation with environmental responsibility. In particular our fndings highlight the efectiveness of TBEC and green solvent systems optimizing scalable and sustainable SPPS processes and improving resource efciency. Thus, we propose a viable pathway to produce the therapeutic peptide ingredient liraglutide signifcantly reducing the environmental impact while maintaining high efficiency and quality of the synthesis.

Scalable and Sustainable DMF-Free Solid-Phase Synthesis of Liraglutide by 1-Tert-Butyl-3-Ethylcarbodiimide-Mediated Couplings and Catch-and-Release Acylation and Purification Strategies / Pacini, Lorenzo; Muthyala, Manoj Kumar; Zitterbart, Robert; Marder, Oleg; Rovero, Paolo; Papini, Anna Maria. - In: INTERNATIONAL JOURNAL OF PEPTIDE RESEARCH AND THERAPEUTICS. - ISSN 1573-3904. - ELETTRONICO. - 31:(2025), pp. 43.1-43.10. [10.1007/s10989-025-10703-4]

Scalable and Sustainable DMF-Free Solid-Phase Synthesis of Liraglutide by 1-Tert-Butyl-3-Ethylcarbodiimide-Mediated Couplings and Catch-and-Release Acylation and Purification Strategies

Pacini, Lorenzo;Rovero, Paolo;Papini, Anna Maria
2025

Abstract

Introduction The growing need for sustainable practices in pharmaceutical manufacturing has stimulated advancements in peptide synthesis. This study focuses on applying green chemistry principles to the synthesis of the Glucagon-Like Peptide-1 analog liraglutide. Material and Methods The safer coupling reagent 1-tert-butyl-3-ethylcarbodiimide (TBEC) was tested in combination with eco-friendly binary solvents such as dimethyl sulfoxide and butyl acetate to propose novel and sustainable solid-phase synthetic and purifcation strategies of liraglutide. Results Two synthetic strategies were developed for liraglutide production. The frst strategy was based on a “direct synthesis”, incorporating a lipidated lysine building block into the peptide sequence, achieving 86% HPLC purity after catch-andrelease purifcation. The second strategy based on “catch-lipidation-and-release” approach, allowed to obtain the peptide precursor without the lipid moiety, which was later linked during a controlled lipidation step. This latter strategy yielded purities exceeding 90% and reduced reliance on preparative HPLC. TBEC minimizes hazardous byproducts, such as hydrogen cyanide, and enhances solvent compatibility, achieving crude purities and yields comparable to conventional syntheses. Conclusion This work underscores the potential of green chemistry to align pharmaceutical innovation with environmental responsibility. In particular our fndings highlight the efectiveness of TBEC and green solvent systems optimizing scalable and sustainable SPPS processes and improving resource efciency. Thus, we propose a viable pathway to produce the therapeutic peptide ingredient liraglutide signifcantly reducing the environmental impact while maintaining high efficiency and quality of the synthesis.
2025
31
1
10
Goal 3: Good health and well-being
Goal 12: Responsible consumption and production
Goal 9: Industry, Innovation, and Infrastructure
Goal 15: Life on land
Pacini, Lorenzo; Muthyala, Manoj Kumar; Zitterbart, Robert; Marder, Oleg; Rovero, Paolo; Papini, Anna Maria
File in questo prodotto:
File Dimensione Formato  
s10989-025-10703-4.pdf

accesso aperto

Tipologia: Pdf editoriale (Version of record)
Licenza: Open Access
Dimensione 1.87 MB
Formato Adobe PDF
1.87 MB Adobe PDF

I documenti in FLORE sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificatore per citare o creare un link a questa risorsa: https://hdl.handle.net/2158/1415135
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 1
  • ???jsp.display-item.citation.isi??? 3
social impact